此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Impacto 2.0: Mobile Smoking Cessation Across Texas

2026年11月3日 更新者:Michael J. Zvolensky, Ph.D.

Impacto 2.0: Addressing Disparities in Smoking Cessation Access and Outcomes for Hispanic Adults Who Smoke in Texas

This is a preliminary efficacy trial that will examine whether Impacto 2.0 produces higher rates of biochemically verified smoking abstinence among Hispanic adults across Texas compared to the NCI quitSTART app. The primary objective is to evaluate the preliminary efficacy of Impacto 2.0 in reducing smoking, tobacco withdrawal, and craving. One hundred Hispanic adults who smoke will be recruited across Texas and followed remotely over an 8-week intervention period with a 3-month post-quit follow-up.

研究概览

地位

尚未招聘

条件

详细说明

This project proposes a preliminary efficacy randomized clinical trial (RCT) testing Impacto 2.0, a culturally adapted, bilingual (Spanish and English), smartphone-based smoking cessation intervention developed and pilot tested among Hispanic adults who smoke.

Impacto was originally developed through a National Institutes of Health (NIH)-funded Phase 1 Small Business Technology Transfer (STTR) project using a community-informed, user-centered design process that integrated input from Hispanic end-users, bilingual developers, and clinical providers serving a predominantly Hispanic population. The app targets anxiety sensitivity (AS), or the fear of anxiety-related bodily sensations, which has been empirically shown to be a robust, modifiable transdiagnostic mechanism that impedes smoking cessation success among Hispanic adults.

In a proof-of-concept open trial of Impacto 1.0, 65.4% of Spanish-speaking Hispanic adult participants reported smoking abstinence at 4 weeks post-quit, with significant reductions in anxiety sensitivity and high rates of feasibility, acceptability, and engagement observed across the sample.

The present project aims to extend Impacto 2.0 to Hispanic adults who smoke across Texas, with a statewide targeted recruitment emphasis on rural and medically underserved regions. These regions include communities where geographic, linguistic, and economic barriers may limit access to evidence-based smoking cessation treatment. By leveraging smartphone-based delivery, the study seeks to increase access to culturally adapted smoking cessation support while evaluating the preliminary efficacy of Impacto 2.0 compared to the National Cancer Institute's (NCI) quitSTART app.

研究类型

介入性

注册 (估计的)

100

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Texas
      • Houston、Texas、美国、77204
        • RESTORE Laboratory: Research on Emotion, Substance Treatment Outcomes, Rehabilitation, and Empowerment
        • 接触:
        • 首席研究员:
          • Micheal J Zvolensky, Ph.D.

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Self-identifies as Hispanic/Latino/a
  • Currently resides in Texas
  • Age 18 years or older
  • Currently smokes combustible cigarettes daily, biochemically verified by expired carbon monoxide >7 ppm using the CoVita iCOquit Smokerlyzer
  • Meets criteria for elevated anxiety sensitivity (cut-off score of 5 on the Short Scale Anxiety Sensitivity Index)
  • Motivated to quit smoking
  • Able to provide informed consent
  • Has daily access to an iPhone or Android smartphone
  • Fluent in English or Spanish

Exclusion Criteria:

  • Current use of vaping/e-cigarettes, cigars, cigarillos, pipes, cannabis products, or other nicotine/tobacco products in addition to combustible cigarettes
  • Current participation in alcohol or drug-use treatment, including smoking-cessation treatment
  • Current psychotherapy for anxiety or depression
  • Concurrent use of medication for anxiety or depression
  • Active suicidality (ideation, intent, and/or plan)
  • Current psychosis
  • Currently pregnant, nursing, or actively trying to conceive, including male participants who report that they or a partner are actively trying to conceive
  • Myocardial infarction within the past 2 weeks
  • Uncontrolled high blood pressure
  • Participants with the ability to become pregnant must provide a negative urine pregnancy test before final eligibility/onboarding

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Impacto 2.0

Participants will use the Impacto 2.0 smartphone application for 8 weeks.

A culturally adapted, bilingual smartphone-based smoking cessation intervention that provides psychoeducation targeting anxiety sensitivity reduction. The app includes four lessons per week across the 8-week intervention period and exercises targeting anxiety sensitivity.

有源比较器:quitSTART

Participants will use the National Cancer Institute's quitSTART smartphone application for 8 weeks.

The National Cancer Institute's quitSTART smartphone smoking cessation application. The app provides tools to help users understand smoking patterns, track smoking habits and urges, and manage cravings.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Biochemically Verified 7-Day Point Prevalence Smoking Abstinence
大体时间:Week 8

Smoking abstinence will be assessed using self-reported 7-day point prevalence abstinence and biochemically verified using the CoVita iCOquit Smokerlyzer. An expired carbon monoxide level <7 ppm will indicate abstinence.

Week 8

次要结果测量

结果测量
措施说明
大体时间
Biochemically Verified 7-Day Point Prevalence Smoking Abstinence
大体时间:Week 16

Smoking abstinence will be assessed using self-reported 7-day point prevalence abstinence and biochemically verified using the CoVita iCOquit Smokerlyzer. An expired carbon monoxide level <7 ppm will indicate abstinence.

Week 16
Tobacco Withdrawal
大体时间:Baseline, Week 4, Week 8, and Week 16

Tobacco withdrawal will be assessed using the revised 15-item Minnesota Nicotine Withdrawal Scale (MNWS), a self-report questionnaire measuring smoking withdrawal symptoms. Items are rated on a 5-point Likert scale ranging from 0 (none) to 4 (severe). A withdrawal severity score is calculated by averaging the core withdrawal symptom items, yielding a score ranging from 0 to 4, with higher scores indicating greater tobacco withdrawal severity.

Baseline, Week 4, Week 8, and Week 16
Tobacco Craving
大体时间:Baseline, Week 4, Week 8, and Week 16

Tobacco craving will be assessed using the 10-item Questionnaire of Smoking Urges-Brief (QSU-B), which measures cigarette craving in the current moment. Items are rated on a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree). The total score is calculated by summing all 10 items, with possible scores ranging from 10 to 70. Higher scores indicate greater cigarette craving.

Baseline, Week 4, Week 8, and Week 16
Anxiety Sensitivity
大体时间:Baseline, Week 4, Week 8, and Week 16

Anxiety sensitivity will be assessed using the 5-item Short Scale Anxiety Sensitivity Index (SSASI), which measures fear of anxiety-related bodily sensations. Items are rated on a 5-point Likert scale ranging from 0 (very little) to 4 (very much). The total score is calculated by summing all five items, with possible scores ranging from 0 to 20. Higher scores indicate greater anxiety sensitivity.

Baseline, Week 4, Week 8, and Week 16

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年2月1日

初级完成 (估计的)

2030年12月31日

研究完成 (估计的)

2030年12月31日

研究注册日期

首次提交

2026年10月26日

首先提交符合 QC 标准的

2026年10月29日

首次发布 (实际的)

2026年11月4日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • STUDY00006201

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

There is no plan to make individual participant data (IPD) available to other researchers.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅